Ensuring Timely Access to Generics Act of 2019
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (May 1, 2019)
Ensuring Timely Access to Generics Act of 2019
This bill requires the Food and Drug Administration (FDA) to consider certain factors in determining whether a petition is submitted for the primary purpose of delaying the approval of a drug application.
The FDA must (1) publish a list of petitions that were submitted with an intent to delay, and (2) establish procedures to refer such petitions to the Federal Trade Commission.
The FDA may establish a timeline for submitting petitions.
What just happenedMay 2, 2019
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMay 1, 2019
- May 2, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - May 1, 2019IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - May 1, 2019IntroReferralIntro-H
Introduced in House
- May 1, 2019IntroReferral1000
Introduced in House